Anti Cd 20 Ocrevus denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applied a Quantity Limit to Ocrevus — and Your Appeal Path

Ocrelizumab (Ocrevus) is administered by intravenous infusion on a schedule defined in the FDA-approved prescribing information. UnitedHealthcare's quantity-limit policy for ocrelizumab caps the number of infusion sessions, vials, or total drug units that will be covered within a defined period. A denial fires when the quantity reflected in the prior-authorization request or on the claim differs from UHC's internal quantity-limit table — even when the prescriber has ordered exactly the schedule described in the FDA-approved label.

Like Humana quantity-limit denials, these are frequently administrative mismatches rather than clinical judgments, and they are highly appealable.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline on your denial notice (typically 180 days under ERISA §503 or applicable state law for non-employer plans).
• External review: Under ACA §2719, quantity-limit denials that involve any medical-necessity judgment are subject to independent external review. The standard filing window is approximately four months from the final internal adverse decision. Expedited review (72-hour decision) is available for clinically urgent situations.
• Right to criteria disclosure: UHC must, on request, provide the specific quantity-limit criteria it applied. You are entitled to see the full Medical Policy before or during the appeal.

## Concrete Steps and Timeline

1. Request the denial letter and the UHC Medical Policy for ocrelizumab. The denial must state the exact quantity limit applied and the policy basis. 2. Compare the quantity limit in UHC's policy with the dosing schedule in the FDA-approved prescribing information for Ocrevus. If UHC's limit matches the FDA-approved schedule, the issue may be a data-entry or billing error — contact your infusion center and UHC Provider Services to correct. 3. If the limit is more restrictive than the label, or if there is a legitimate clinical need for a modified schedule, proceed to formal appeal. 4. File the internal appeal with documentation addressing both the administrative and clinical dimensions. 5. If the internal appeal is denied, file for external review within the four-month deadline.

## Documentation to Gather

• FDA prescribing label dosing schedule: A reference to the ocrelizumab prescribing information showing the approved dosing interval and the number of doses per year. Your neurologist's office can attach the package insert.
• Prescriber attestation of label-concordant dosing: A letter from your neurologist stating that the quantity requested matches the FDA-approved dosing schedule and is medically necessary to maintain therapeutic continuity.
• Infusion history: Records of prior infusions (dates, doses as administered, infusion site) showing the pattern consistent with the label-approved schedule.
• Diagnosis and disease-activity documentation: Chart notes confirming ongoing MS diagnosis, subtype, and disease status — establishing why uninterrupted dosing on schedule is medically necessary.
• Medical-necessity letter addressing any schedule variation: If the prescriber has requested a quantity that varies from the standard schedule for a clinical reason, the letter must explain that reason explicitly.

## Criteria-Mapping Structure

Obtain UHC's quantity-limit policy for ocrelizumab. For each quantity-related requirement:

| Policy Quantity Limit | Your Evidence | |---|---| | Maximum infusions per coverage period | FDA label schedule; prescriber order showing [N] infusions per year | | Maximum units/vials per infusion event | FDA label dosing; prescriber order matching label | | Continuity requirement (if any) | Infusion history showing prior on-schedule dosing | | Medical justification for requested quantity | Neurologist letter addressing any deviation |

When the requested quantity precisely matches what the FDA-approved label specifies, the appeal argument is straightforward: the plan's quantity limit, as applied, would require the patient to receive less drug than the FDA-approved therapeutic dose — which is a compelling basis for reversal at both internal appeal and external review.